| Cash Flow | 2025-09-30 | 2025-06-30 |
|---|---|---|
| Net loss | -17,170 | -10,688 |
| Depreciation | 222 | 146 |
| Interest expense and amortization of debt discount on term loans (related party) | 1,586 | 1,118 |
| Stock-based compensation for services | 152 | - |
| Amortization of prepaid insurance | 738 | 493 |
| Stock-based compensation | 478 | 306 |
| Change in fair value of private warrant liability | 339 | - |
| Change in fair value of forward purchase agreement put option liability | - | 0 |
| Change in fair value of publicly traded warrant liability | -129 | -162 |
| Change in fair value of forward purchase agreement warrant liability | -522 | -458 |
| Change in operating lease right-of-use asset (related party) | -39 | 51 |
| Change in inventory reserve | 68 | 10 |
| Accounts receivable, net | -3 | 5 |
| Other receivable | -761 | -760 |
| Inventories | -1 | -111 |
| Prepaid expenses and other current assets | 74 | 42 |
| Accounts payable | 973 | -33 |
| Operating lease liability (related party) | 1 | -44 |
| Accrued expenses | 216 | 312 |
| Product warranty liability | -120 | -60 |
| Net cash used in operating activities | -12,516 | -8,185 |
| Purchases of property and equipment | 7 | 7 |
| Deposits on equipment not yet placed in service | - | 0 |
| Net cash used in investing activities | -7 | -7 |
| Payments on insurance financing loans | 636 | 469 |
| Proceeds from the issuance of term loans (related party) | 10,000 | 10,000 |
| Dividends paid to stockholders of series a preferred stock | 1,820 | 1,820 |
| Proceeds from the sale of common stock associated with forward purchase agreement, net of transaction costs | - | 0 |
| Payment made for extinguishment of term loans (related party) | 100 | - |
| Proceeds from the issuance of common stock from atm offering | 414 | 204 |
| Proceeds from issuance of common stock under employee stock purchase plan | 77 | 77 |
| Proceeds from exercise of forward purchase agreement warrants | 158 | - |
| Proceeds from the issuance of common stock and investor warrants from registered direct offering | 2,500 | - |
| Net cash provided by financing activities | 10,593 | 7,992 |
| Effect of exchange rate changes on cash | 3 | 4 |
| Net (decrease) increase in cash | -1,927 | -196 |
| Cash and cash equivalents at beginning of period | 5,483 | - |
| Cash and cash equivalents at end of period | 3,556 | - |
Envoy Medical, Inc. (COCH)
Envoy Medical, Inc. (COCH)